Application of schizochytrium limacinum mutant strain and grease produced by schizochytrium limacinum mutant strain in microcapsules
The ion-beam microbial mutagenesis breeding technology was used to screen out the schizophrenia mutant strain CABIO-A-2-VII, which solved the metabolic bottleneck problem of microbial fermentation and production of EPA and DHA, achieved high content of oil and fat, and significantly improved the quality of oil and fat in microcapsule applications.
Patent Information
- Application Number
- CN202411966768.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-12-30
- Publication Date
- 2025-03-28
- Estimated Expiration
- 2044-12-30
AI Technical Summary
When the prior art uses microbial fermentation to produce omega-3 series polyunsaturated fatty acids such as EPA, there is a metabolic bottleneck in the fatty acid synthesis pathway, which limits the content of EPA and DHA, and the application effect of oils and fats in microcapsules is not good.
Through ion beam microbial mutagenesis breeding technology, a schizochytrium mutant strain CABIO-A-2-VII was screened. During the fermentation process, the EPA content of this strain was greatly increased, the C14:0 content was high, the DHA content was ≥40%. The oil produced was low in surface oil content and peroxide value and had no fishy smell when preparing microcapsules.
Under conventional fermentation process, the DHA content in the oil and fat is ≥40%, the EPA content in the oil and fat is >2%, and the C14:0≥12%, and the embedding effect and quality of the oil and fat in the microcapsules are improved.